---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009740"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:51:25.466400+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected

## Summary
- Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.
- Vonaprument Phase 3 ARCHER II topline data for geographic atrophy expected second half of 2026; enrolled 659 patients.
- ANX1502 proof-of-concept data in cold agglutinin disease (CAD) anticipated in 2026; oral C1 inhibitor.
- Financial position funds operations into late 2027, well past anticipated key milestones.

## SEC filing metadata
- accession: 0001193125-26-009740
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312526009740/0001193125-26-009740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312526009740/d75965d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009740
- JSON: https://secwatch.observer/filing/0001193125-26-009740.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.